Home
Productsindex
Gene
BioActive Proteinsindex
BioActive Biomarker Proteinslists
BioActive Human ATM oncogenic mutation Recombinant Protein,Fc Tag
SGRP00658
BioActive Human ATM oncogenic mutation Recombinant Protein,Fc Tag
Source:Full length Human ARID1A oncogenic mutation, expressed in HEK293 cells.
SKU:SGRP00658-100UG
Product Name:BioActive Human ATM oncogenic mutation Recombinant Protein,Fc Tag
Product Description:Human ATM oncogenic mutation expressed in HEK293 cells with activity confimed by ELISA.
SKU:SGRP00658-100UG
Product Name:BioActive Human ATM oncogenic mutation Recombinant Protein,Fc Tag
Product Description:Human ATM oncogenic mutation expressed in HEK293 cells with activity confimed by ELISA.
PROPERTIES
Biological Activity:
Fully biologically active
Purity:
> 95% by SDS-PAGE & HPLC
Endotoxin Level:
< 1.0 EU per μg protein as determined by the LAL method
Expression System:
HEK293 Cells
Format:
Recombinant
Species:
Human
Applications:
Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPLC
Form:
Lyophilized from sterile PBS, pH 7.41
Concentration:
N/A
Stability and Storage:
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:
Reconstitute with Phosphate Buffered Saline.
Related Categories
BioActive Biomarker Proteins
Background

Gene Accession

Q13315

Gene Alias

Protein names Recommended name Serine-protein kinase ATM EC number EC:2.7.11.1 6 Publications (UniProtKB | ENZYME | Rhea) Alternative names Ataxia telangiectasia mutated (A-T mutated) Gene names Name ATM

Background

Germ-line mutations of the ataxia telangiectasia mutated (ATM) gene result in the well-characterized ataxia telangiectasia syndrome, which manifests with an increased cancer predisposition, including a 20% to 30% lifetime risk of lymphoid, gastric, breast, central nervous system, skin, and other cancers. Somatic ATM mutations or deletions are commonly found in lymphoid malignancies, as well as a variety of solid tumors. Such mutations may result in chemotherapy resistance and adverse prognosis, but may also be exploited by existing or emerging targeted therapies that produce synthetic lethal states.

RECOMMENDED PRODUCTS
BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
ABL1

SGRP00624

BioActive Human ABL1 (V299L,T315A,F317L,F317V,F317I,F317C) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
ABL1

SGRP00628

BioActive Human ABL1 (T315A,F317L,F317V,F317I,F317C,V299L) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
AKT1

SGRP00630

BioActive Human AKT1 (Q79K,E17K) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
AKT1

SGRP00631

BioActive Human AKT1 (H238Y) Recombinant Protein,Fc Tag
View Price and Availability
BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
ALK

SGRP00637

BioActive Human ALK (G1123S) Recombinant Protein,Fc Tag
View Price and Availability
0.125093s